Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Enalapril maleate 5mg; ;
Multichem NZ Limited
Enalapril maleate 5 mg
5 mg
Tablet
Active: Enalapril maleate 5mg Excipient: Croscarmellose sodium Hypromellose Lactose monohydrate Maleic acid Sodium stearyl fumarate
Blister pack, PVDC coated PVC/aluminium, 30 tablets
Prescription
Prescription
Zhejiang Huahai Pharmaceutical Co Ltd
All grades of essential hypertension.
Package - Contents - Shelf Life: Blister pack, PVDC coated PVC/aluminium - 30 tablets - 24 months from date of manufacture stored at or below 25°C protect from light - Bottle, plastic, HDPE bottle and screw cap - 100 tablets - 24 months from date of manufacture stored at or below 25°C protect from light
2013-08-06
NEW ZEALAND DATA SHEET ETHICS ENALAPRIL Enalapril maleate 5 mg, 10 mg and 20 mg tablets Page 1 of 13 1. NAME OF THE MEDICINAL PRODUCT Ethics Enalapril 5 mg, tablet Ethics Enalapril 10 mg, tablet Ethics Enalapril 20 mg, tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg of enalapril maleate as the active ingredient. Each tablet contains 10 mg of enalapril maleate as the active ingredient. Each tablet contains 20 mg of enalapril maleate as the active ingredient. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ethics Enalapril Tablets 5 mg are white to off-white, round, flat faced beveled edge tablets with breakline on one side and ‘5’ debossed on the other side. Ethics Enalapril 5mg tablets are not to be divided. Ethics Enalapril Tablets 10 mg are white to off white, round, flat faced, beveled edge tablets with breakline on one side and ‘10’ debossed on the other side. Ethics Enalapril Tablets 20 mg are white to off white, round, flat faced, beveled edge tablets with breakline embossed on one side and ‘20’ debossed on the other side. Ethics Enalapril Tablets is the maleate salt of enalapril, a derivative of two amino acids, L-alanine and L-prolin. Following oral administration, enalapril is rapidly absorbed and then hydrolysed to enalaprilat, which is a highly specific, long acting, non-sulphydryl angiotensin converting enzyme inhibitor. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of: • All grades of essential hypertension • Renovascular hypertension • All degrees of heart failure In patients with symptomatic heart failure, Ethics Enalapril is also indicated to: • Improve survival • Retard the progression of heart failure • Reduce hospitalisation for heart failure • Prevention of symptomatic heart failure In asymptomatic patients with left ventricular dysfunction, Ethics Enalapril is indicated to: • Retard the development of symptomatic heart failure • Reduce hospitalisation for heart failure • Prevention of coronar Read the complete document